Veradigm vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare data company with 130K connected physicians; EHR-connected real-world evidence network for pharma analytics rebranded from Allscripts competing with IQVIA for life sciences data.
About
Veradigm (formerly Allscripts Healthcare) is a healthcare information technology company providing EHR-connected data network services, physician practice management software, pharmacy solutions, and life sciences data analytics — operating at the intersection of clinical care delivery and healthcare data commercialization. Listed on NASDAQ (NASDAQ: MDRX) and headquartered in Chicago, Illinois, Veradigm rebranded from Allscripts in 2023 as it refocused from clinical EHR software toward data and analytics services, generating approximately $600 million in annual revenue.\n\nVeradigm's core asset is its network of approximately 130,000 connected physicians and tens of millions of de-identified patient records accessible through its data products. The Veradigm Network connects ambulatory physician practices running Allscripts EHR (Professional EHR, TouchWorks) and enables data flows for prescription analytics, clinical decision support, and real-world evidence (RWE) for pharmaceutical companies. The life sciences data business provides pharma clients with prescription analytics, patient journey data, and clinical research data services.\n\nIn 2025, Veradigm is in strategic transition — the company has been exploring alternatives to maximize shareholder value, including potential sale or acquisition, following activist investor pressure. The EHR product portfolio (Allscripts-branded physician practice software) competes with athenahealth, Epic, and eClinicalWorks in the ambulatory market, though Veradigm's focus has shifted toward its data network value rather than competing head-to-head in EHR functionality. Veradigm competes with IQVIA, Komodo Health, and Definitive Healthcare for life sciences real-world data. The 2025 strategy focuses on growing the data analytics and real-world evidence business while managing the legacy EHR product base.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.